Bumper Offer - Urjas oil Just @ Rs. 1
Lamitor DT 25 Tablet, a prescription drug, is manufactured in various forms such as Tablet. Primarily, it is used for the treatment of Seizures. Secondary and off-label uses of Lamitor DT 25 Tablet have also been mentioned below.
The optimal dosage of Lamitor DT 25 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Refer to the dosage section for a detailed discussion.
Apart from the aforementioned side effects, Lamitor DT 25 Tablet can also lead to other problems, which have been listed below. Usually, these side effects of Lamitor DT 25 Tablet go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Lamitor DT 25 Tablet's effect during pregnancy is Moderate and Moderate while nursing. Warnings related to Lamitor DT 25 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Lamitor DT 25 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Depression are examples of such conditions. The section on Lamitor DT 25 Tablet contraindications lists all such conditions.
Besides this, Lamitor DT 25 Tablet may also have severe interaction with some medicines. See below for a complete list.
In addition to these precautions, you may also note that Lamitor DT 25 Tablet is not safe while driving, and is is not addictive in nature.
Lamitor DT 25 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Is the use of Lamitor DT 25 Tablet safe for pregnant women?
Lamitor may cause moderate side effects during pregnancy. If you feel its harmful effects, then stop taking this drug immediately, and do not take Lamitor again without your doctor's advice.
Is the use of Lamitor DT 25 Tablet safe during breastfeeding?
Lamitor can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Lamitor DT 25 Tablet on the Kidneys?
Lamitor rarely affects the kidneys.
What is the effect of Lamitor DT 25 Tablet on the Liver?
Lamitor may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Lamitor DT 25 Tablet on the Heart?
Using Lamitor does not have any harmful effects on the heart.
Lamitor DT 25 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Lamitor DT 25 Tablet unless your doctor advises you to do so -
Is this Lamitor DT 25 Tablet habit forming or addictive?
No, there is no any evidence that Lamitor DT 25 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Lamitor DT 25 Tablet. So it is best to avoid driving.
Is it safe?
Yes, but consume Lamitor DT 25 Tablet only on doctor's advice.
Is it able to treat mental disorders?
Lamitor DT 25 Tablet has been seen to have positive effect on patients with mental disorders.
Interaction between Food and Lamitor DT 25 Tablet
It is safe to take Lamitor DT 25 Tablet with food.
Interaction between Alcohol and Lamitor DT 25 Tablet
Taking Lamitor DT 25 Tablet with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 742- 744
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 419
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lamictal (lamotrigine)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lamitan (lamotrigine)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 742- 744
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 419
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lamictal (lamotrigine)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lamitan (lamotrigine)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 742- 744
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 419
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lamictal (lamotrigine)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lamitan (lamotrigine)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 742- 744
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 419
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lamictal (lamotrigine)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lamitan (lamotrigine)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 742- 744
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 419
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lamictal (lamotrigine)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lamitan (lamotrigine)
